Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma

Leukemia volume 21, pages 524–528 (2007)Cite this article

Abstract

Single-agent bortezomib, a potent, selective and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL). Objective response is achieved in up to 45% of the patients; however, complete remission rates are low and duration of response proved to be short. These limitations may be overcome by combining proteasome inhibition with conventional chemotherapy. Here we present two case reports and in vitro data suggesting synergistic efficacy of bortezomib combined with cytarabine in MCL. Interestingly, efficacy in vitro correlated with sequence of treatment, indicating that pretreatment with cytarabine, followed by proteasome inhibition, may be the preferred approach.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Ciechanover A . The ubiquitin–proteasome proteolytic pathway. Cell 1994; 79: 13–21.

    Article  CAS  PubMed  Google Scholar 

  2. Adams J . The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349–360.

    Article  CAS  PubMed  Google Scholar 

  3. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    Article  CAS  PubMed  Google Scholar 

  4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

    Article  CAS  PubMed  Google Scholar 

  5. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420–4427.

    Article  CAS  PubMed  Google Scholar 

  6. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684.

    Article  CAS  PubMed  Google Scholar 

  7. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675.

    Article  CAS  PubMed  Google Scholar 

  8. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105–2112.

    Article  CAS  PubMed  Google Scholar 

  9. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM . Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624–4631.

    CAS  PubMed  Google Scholar 

  10. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380.

    Article  CAS  PubMed  Google Scholar 

  11. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065.

    Article  CAS  PubMed  Google Scholar 

  12. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992.

    Article  CAS  PubMed  Google Scholar 

  13. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071.

    Article  CAS  PubMed  Google Scholar 

  14. Chou TC, Talalay P . Generalized equations for the analysis of inhibitions of Michaelis–Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115: 207–216.

    Article  CAS  PubMed  Google Scholar 

  15. Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S et al. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1983; 1: 689–694.

    Article  CAS  PubMed  Google Scholar 

  16. Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587–593.

    Article  CAS  PubMed  Google Scholar 

  17. Sampath D, Rao VA, Plunkett W . Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22: 9063–9074.

    Article  CAS  PubMed  Google Scholar 

  18. MacFarlane M, Merrison W, Bratton SB, Cohen GM . Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 2002; 277: 36611–36616.

    Article  CAS  PubMed  Google Scholar 

  19. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM . Caspase activation inhibits proteasome function during apoptosis. Mol Cell 2004; 14: 81–93.

    Article  CAS  PubMed  Google Scholar 

  20. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226–8232.

    CAS  PubMed  Google Scholar 

  21. Nakanishi C, Toi M . Nuclear factor–kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297–309.

    Article  CAS  PubMed  Google Scholar 

  22. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ . Inhibition of constitutive NF–kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88–95.

    Article  CAS  PubMed  Google Scholar 

  23. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257–264.

    Article  CAS  PubMed  Google Scholar 

  24. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393–403.

    Article  CAS  PubMed  Google Scholar 

  25. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294–1305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Friedrich-Baur-Stiftung (0078/2005), Munich, and the European Union: 6 FP, Translational research on promising predictive and prognostic markers: ‘European MCL Network’ (contract no. 503351) and Lymphoma Research Foundation Grant ‘European MCL Network’.

Author information

Author notes

  1. O Weigert and A Pastore: These authors contributed equally to this work

Authors and Affiliations

  1. Department of Internal Medicine III, University of Munich, University Hospital Grosshadern, Munich, Germany

    O Weigert, A Pastore, N Lang, W Hiddemann & M Dreyling

  2. GSF-National Research Center for Environment and Health, Haematologicum, Munich, Germany

    O Weigert, A Pastore, M Rieken & M Dreyling

Authors
  1. O Weigert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Pastore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Rieken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Dreyling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Dreyling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weigert, O., Pastore, A., Rieken, M. et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 21, 524–528 (2007). https://doi.org/10.1038/sj.leu.2404511

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404511

Keywords

This article is cited by

Search

Advanced search

Quick links